SOLV · 8-K · 20261105PR000055
Guidance and Outlook
Solventum Corp · 2026-11-05 · Importance 62 · Surprise 68 · In source text
For full-year 2026, Solventum moved its organic sales growth outlook toward the high end of its 2.5%–3.0% range, or toward the high end of 3.5%–4.0% excluding an approximately 100-basis-point SKU-exit impact. It raised adjusted EPS guidance to $7.20–$7.30 from $7.10–$7.20. The company affirmed free cash flow guidance of $200 million–$300 million.
Key facts
- Solventum raised full-year 2026 adjusted diluted EPS guidance to $7.20–$7.30 from $7.10–$7.20. source
- Solventum expects full-year 2026 organic sales growth toward the high end of its +2.5% to +3.0% range. source
- Solventum expects full-year 2026 organic sales growth toward the high end of +3.5% to +4.0%, excluding approximately 100 basis points of SKU exit impact. source
- Solventum affirmed full-year 2026 free cash flow guidance of $200 million to $300 million. source
- Solventum is reviewing strategic alternatives for its Health Information Systems business, including whether alternatives can be identified, pursued and deliver potential benefits; timing is uncertain. source
Impact estimates
| metric | direction | stage | expected | basis |
|---|---|---|---|---|
| revenue | positive | committed | +2.3% | Solventum expects full-year 2026 organic sales growth toward the high end of +3.5% to +4.0%, excluding approximately 100 basis points of… |
| cash | positive | committed | +1.5% | Solventum affirmed full-year 2026 free cash flow guidance of $200 million to $300 million. |
| net_income | positive | committed | — | Solventum raised full-year 2026 adjusted diluted EPS guidance to $7.20–$7.30 from $7.10–$7.20. |